AppLovin's stock had its best day ever Thursday, rising 46% following the company's latest earnings, and it gained another 18% in Friday's session. That could reflect investor perception of how far ...

Biopharma stocks are rarely suitable for short-term investing, so hold onto them. Summit Therapeutics may have a powerful new ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. Eight ...

Join STAT to explore how the biopharma industry is advancing outcome-based multimodal therapeutics on Nov. 22.

In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $14.71 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise ...

Fintel reports that on November 4, 2024, JMP Securities initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today ...

The ISG Digital Business Summit, to be held at the Westin Dallas Stonebriar Golf Resort & Spa, will open with an industry spotlight conversation with Diane Schwarz, vice president and chief ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...